Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...
Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost ...
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is ...
View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback